Australia adopts landmark new prostate cancer detection guidelines

Australia has adopted new national guidelines for the early detection of prostate cancer, marking the biggest update to testing and diagnosis recommendations in more than a decade.

The 2026 Clinical Practice Guidelines for the Early Detection of Prostate Cancer in Australia, developed by the Prostate Cancer Foundation of Australia (PCFA) and approved by the National Health and Medical Research Council, replace the previous guidelines introduced in 2016.

The new recommendations aim to help doctors find aggressive prostate cancers earlier, while reducing unnecessary tests, biopsies and treatment.

One of the biggest changes is that GPs are now encouraged to discuss prostate-specific antigen (PSA) testing with men from the age of 50. Men at higher risk, including those with a strong family history or inherited genetic risk, should start these conversations from age 45.

The guidelines also recommend that men have a multiparametric MRI scan before a biopsy where appropriate. This can help doctors identify significant cancers more accurately and reduce the number of unnecessary invasive procedures.

Another major change is that men aged 70 and over may continue PSA testing after an individual assessment with their doctor. Previous guidelines had set an age cut-off for routine testing.

New PSA testing pathways have also been introduced, with recommendations based on a man’s age and personal risk factors.

Australia is among the first countries to introduce a modern, evidence-based approach to prostate cancer early detection, giving doctors clearer guidance on who should be tested and when.

The review behind the new guidelines was one of the most comprehensive undertaken in Australian men’s health.

Over two years, a committee of clinicians, researchers, consumers and policy experts reviewed more than 27,000 scientific abstracts, assessed more than 1,100 research papers and considered more than 1,400 public submissions.

Professor Jeff Dunn AO, Chair of the Guideline Steering Committee, said the recommendations reflected years of scientific research and collaboration.

“These Guidelines represent the culmination of years of scientific work, national collaboration, and rigorous evaluation of the evidence.

“Much has changed over the past decade. The evidence has matured, diagnostic technologies have advanced, and clinical practice has evolved substantially.

“For the first time, Australia now has a contemporary national framework that better balances the benefits of detecting aggressive prostate cancer early with the need to minimise unnecessary harms.

“Our ambition is simple: to ensure every Australian man has access to the very best evidence available, giving him the greatest possible opportunity to detect clinically significant prostate cancer early, receive timely treatment where required, and ultimately reduce his risk of dying from this disease.”

Adjunct Professor Peter Heathcote, Chair of the Guideline Expert Advisory Panel, said advances in technology had changed the way prostate cancer is diagnosed.

“Modern prostate cancer diagnosis is no longer based on a PSA blood test alone.

“Today’s diagnostic pathway incorporates individual risk assessment, shared decision-making, multiparametric MRI before biopsy, targeted biopsy techniques, and active surveillance for men with low-risk disease.

“These advances allow clinicians to identify clinically significant cancers more accurately while reducing unnecessary biopsies, significantly reducing risks of overtreatment, and ensuring we protect men’s quality of life while managing individual risks.”

The updated guidelines also include stronger recommendations for men with a significant family history, inherited genetic risk and other groups more likely to develop aggressive prostate cancer.

They place greater emphasis on shared decision-making between men and their doctors and support active surveillance for suitable low-risk cancers.

PCFA Chief Executive Anne Savage said the next step was ensuring the guidelines are widely adopted.

“Developing world-class Guidelines is only half the task. Now we must ensure they are implemented.

“Evidence only saves lives when it reaches the men who need it. Australian men need to understand their individual risk, know when to have the conversation with their GP, and be supported by clinicians with access to the latest evidence.”

Prostate cancer is Australia’s most commonly diagnosed cancer.

Almost 29,000 Australian men are expected to be diagnosed this year and nearly 4,000 are expected to die from the disease.

Around 300,000 Australian men are currently living after a prostate cancer diagnosis. Men with a family history face around double the risk of developing prostate cancer, while men living in regional and remote Australia have poorer outcomes and a higher risk of dying from the disease.